UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 110

Sortiert nach

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

Hepatology communications, 2021-04, Vol.5 (4), p.573-588

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

The Lancet (British edition), 2018-11, Vol.392 (10160), p.2180-2193

2018

Link zum Volltext

Verfügbarkeit prüfen

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

Obesity (Silver Spring, Md.), 2019-01, Vol.27 (1), p.41-49

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Diabetes, obesity & metabolism, 2020-06, Vol.22 (6), p.938-946

2020

Link zum Volltext

Verfügbarkeit prüfen

An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program

Expert review of endocrinology & metabolism, 2023-03, Vol.18 (2), p.111-130

Frías, Juan Pablo

2023

Link zum Volltext

Verfügbarkeit prüfen

Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program

The journal of clinical endocrinology and metabolism, 2024-01, Vol.109 (2), p.557-568

2024

Link zum Volltext

Verfügbarkeit prüfen

Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes

Current medical research and opinion, 2019-04, Vol.35 (4), p.689-695

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D, AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials

Diabetes, obesity & metabolism, 2023-08, Vol.25 (8), p.2084-2095

2023

Link zum Volltext

Verfügbarkeit prüfen

The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device

Clinical therapeutics, 2020-01, Vol.42 (1), p.94-107.e5

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes

Journal of diabetes and its complications, 2019-03, Vol.33 (3), p.236-242

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial

Diabetes, obesity & metabolism, 2020-09, Vol.22 (9), p.1567-1576

2020

Link zum Volltext

Verfügbarkeit prüfen

Prioritising injectable therapies in the management of type 2 diabetes

The lancet. Diabetes & endocrinology, 2019-07, Vol.7 (7), p.505-508

Frias, Juan Pablo

2019

Link zum Volltext

Verfügbarkeit prüfen

Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes

Expert review of endocrinology & metabolism, 2019-03, Vol.14 (2), p.75-83

Frias, Juan Pablo

2019

Link zum Volltext

Verfügbarkeit prüfen

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Cell metabolism, 2017-08, Vol.26 (2), p.343-352.e2

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial

Diabetes care, 2022-07, Vol.45 (7), p.1592-1600

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes

The Journal of family practice, 2018-06, Vol.67 (6 suppl), p.S25-S34

Frias, Juan P

2018

Link zum Volltext

Verfügbarkeit prüfen

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

The New England journal of medicine, 2021-03, Vol.384 (12), p.1113-1124

2021

Link zum Volltext

Verfügbarkeit prüfen

Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials

The review of diabetic studies, 2023-03, Vol.19 (1), p.14-27

2023

Link zum Volltext

Verfügbarkeit prüfen

New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin

Current diabetes reports, 2017-10, Vol.17 (10), p.91-91, Article 91

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

Diabetes care, 2018-09, Vol.41 (9), p.1938-1946

2018

Link zum Volltext

Verfügbarkeit prüfen

Obesity among Latinx people in the United States: A review

Obesity (Silver Spring, Md.), 2023-02, Vol.31 (2), p.329-337

2023

Link zum Volltext

Verfügbarkeit prüfen

78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

You have access78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)

Diabetes (New York, N.Y.), 2021-06, Vol.70

2021

Link zum Volltext

Verfügbarkeit prüfen

BIO89-100 Demonstrated Robust Reductions in Liver Fat, Improved Metabolic Parameters, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH

Metabolism, clinical and experimental, 2022-03, Vol.128, p.155016, Article 155016

2022

Link zum Volltext

Verfügbarkeit prüfen

836-P: A Prebiotic Fiber Blend Improved Postprandial Glucose (PPG) and Time in Range (TIR) as Evaluated by Continuous Glucose Monitoring (CGM) in Healthy Subjects with Normal Glucose Tolerance

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 110

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(105)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(62)
Life Sciences & Biomedicine
(53)
Humans
(33)
Diabetes
(22)
Female
(19)
Male
(19)
Diabetes Mellitus
(17)
Diabetes Mellitus, Type 2 - Drug Therapy
(17)
Endocrinology & Metabolism
(17)
Middle Aged
(17)
Adult
(15)
Glucose
(15)
Patients
(15)
Body Weight
(14)
Type 2 Diabetes
(14)
Hypoglycemia
(12)
Insulin
(11)
Metabolism
(11)
Glucagon
(9)
Liver Diseases
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program

Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program

Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes

Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D, AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials

The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device

Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial

Prioritising injectable therapies in the management of type 2 diabetes

Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial

Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials

New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

Obesity among Latinx people in the United States: A review

78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)

You have access78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)

BIO89-100 Demonstrated Robust Reductions in Liver Fat, Improved Metabolic Parameters, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH

836-P: A Prebiotic Fiber Blend Improved Postprandial Glucose (PPG) and Time in Range (TIR) as Evaluated by Continuous Glucose Monitoring (CGM) in Healthy Subjects with Normal Glucose Tolerance

Suchergebnisse filtern